Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the all-in-one-wp-security-and-firewall domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/ctt_pro/public_html/wp-includes/functions.php on line 6114
Recombinant vaccine against rabbit haemorrhagic disease – Technology Transfer Office

Faculty: Biotechnology UG&MUG

Offer details

TECHNICAL OFFER
nr 030/2017/2
SECTOR
rabbit farming, vaccines, veterinary medicine
AUTHORS
Prof. Bogusław Szewczyk, MWB UG
PhD Beata Gromadzka, MWB UG

Andrzej Fitzner, PIW/PIB
Andrzej Kęs, PIW/PIB
FACULTY
Biotechnology UG&MUG

Commercialization

Spin off
, Licence, Sale of property rights
IP PROTECTION
The invention is the subject of Polish patent protection Pat. 205229, UPRP
TECHNOLOGY READINESS LEVEL
TRL 4
Technology validated in laboratory conditions

Recombinant vaccine against rabbit haemorrhagic disease

Rekombinowana szczepionka przeciwko chorobie krwotocznej królików (RHD)

Rabbit haemorrhagic disease (RHD) is a viral disease which poses a serious threat for both rabbit farmers and rabbit owners, due to its contagiousness and high mortality of infected animals. Aforementioned factors neccessitate culling of not only actually infected individuals, but also animals suspected of contact with infected ones, resulting in severe economic losses in farming inducstry.

Despite numerous research efforts focused on recombinant RHD vaccines, continuing need for effective marker vaccines exists among veterinary services, farmers, breeders and rabbit owners. Such a vaccine should not only provide effective protection of animals, but also allow users to distinguish between infected animals and vaccinated individuals.

Technology developed by scientists from University of Gdańsk allows for production of recombinant capsid protein with haemagglutinating and antigenic properties, capable of forming pseudoviral (VLP) particles and thus stimulating production of antibodies       in vaccinated animals. In addition, marker properties of developed vaccine provide effective means of immunological differentiation between already vaccinated animals and those infected with RHD.

Technology related to offer no. 029/2017/1

Download printable offer

Get in touch